Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
04/2003
04/10/2003WO2003029289A2 Fragements of heat shock proteins and their use
04/10/2003WO2003029288A2 Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same
04/10/2003WO2003029284A1 Anti-hiv agent
04/10/2003WO2003029276A2 Copolymers for suppression of autoimmune diseases, and methods of use
04/10/2003WO2003029268A1 Androstane 17-beta-carboxamides as androgen receptor modulators
04/10/2003WO2003029253A1 4-oxoquinolizine antimicrobials having 2-pyridone skeleton as partial structure
04/10/2003WO2003029242A1 NF-λB INHIBITORS
04/10/2003WO2003029237A1 Products of condensations of hydroxycoumarin derivatives with aromatic and aliphatic dialdehydes, their preparation and antiviral action thereof
04/10/2003WO2003029218A1 Novel nitrogenous compound and use thereof
04/10/2003WO2003029206A1 Preparation of hiv protease inhibitors
04/10/2003WO2003029201A1 Methods and compositions for treating or preventing bacterial infection
04/10/2003WO2003029198A1 Novel urea oligomers, the preparation method thereof and pharmaceutical compositions containing same
04/10/2003WO2003029183A1 Method of synthesising chicoric acid
04/10/2003WO2003028767A2 Water-in-oil emulsions comprising vinyl polymers carrying ethylene oxide groups in side chains, compositions and methods
04/10/2003WO2003028766A1 Water-in-oil emulsions comprising vinyl polymers carrying acidic groups in side chains, compositions, and methods
04/10/2003WO2003028762A1 Novel antimicrobial resistance blocking compositions
04/10/2003WO2003028759A1 Rsv gene expression vaccine
04/10/2003WO2003028755A1 Method for treating hepatitis c virus infection in treatment failure patients
04/10/2003WO2003028754A1 Method for treating hepatitis c virus infection in treatment failure patients
04/10/2003WO2003028748A1 A method of extracting deoxyadenosins components from cordyceps sinensis
04/10/2003WO2003028746A1 Method for producing extracts of pelargonium sidoides and/or pelargonium reniforme, and the use of said extracts
04/10/2003WO2003028741A1 Composition of hypochlorous acid and its applications
04/10/2003WO2003028738A2 Anti-infectious carbohydrates
04/10/2003WO2003028737A1 Anti-viral agents and in-vitro method for the identification of candidates able to inhibit binding of polymerase to epsilon
04/10/2003WO2003028736A2 Pharmaceutical preparations comprising alkyl phosphocholine compounds in liposomes which may be sterile-filtered or heat-sterilised
04/10/2003WO2003028722A1 Treatment of hepatitis b virus infection with human monoclonal antibodies
04/10/2003WO2003028720A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
04/10/2003WO2003028705A1 Pharmaceutical compositions comprising colloidal silicon dioxide
04/10/2003WO2003028701A2 Liposomes containing (ether)lysolecithins
04/10/2003WO2003028700A2 Water soluble nanoparticles of hydrophilic and hydrophobic active materials
04/10/2003WO2003028665A2 Methods for the purification of levofloxacin
04/10/2003WO2003028664A2 Preparation of levofloxacin and forms thereof
04/10/2003WO2003028661A2 Adjuvanted meningococcus compositions
04/10/2003WO2003028656A2 Adjuvant compositions
04/10/2003WO2003028634A2 Method of treatment using ligand-immunogen conjugates
04/10/2003WO2003028632A2 Development of a preventive vaccine for filovirus infection in primates
04/10/2003WO2003028630A2 Methods and compositions for modulating interleukin-21 receptor activity
04/10/2003WO2003028626A2 Glucagon-like peptides (glp-1) and treatment of respiratory distress
04/10/2003WO2003017935A9 Human antibodies specific for interleukin 15 (il-15)
04/10/2003WO2003015711A9 Combination motif immune stimulatory oligonucleotides with improved activity
04/10/2003WO2003007971A9 Improved heteropolymer complexes and methods for their use
04/10/2003WO2003002598A3 Peptides for use as translocation factors
04/10/2003WO2003000709A9 Sialic acid derivatives for use as siglec inhibitors
04/10/2003WO2003000175A3 Pediatric formulation of gatifloxacin
04/10/2003WO2002102793A3 Quinazolinediones as antibacterial agents
04/10/2003WO2002100417A3 Use of glycosaminoglycans for the treatment of hiv-associated nephropathy
04/10/2003WO2002096467A3 Pharmaceutical use for secreted bacterial effector proteins
04/10/2003WO2002094189A3 Compositions and methods for treating or preventing convulsions or seizures
04/10/2003WO2002089738A3 Proteomimetic compounds and methods
04/10/2003WO2002087502A3 Antibodies abolish prion propagation and promote clearance of infectivity
04/10/2003WO2002083103A3 Pharmaceutical product with reticulated crystalline microstructure
04/10/2003WO2002081504A3 Multimerization of hiv-1 vif protein as a therapeutic target
04/10/2003WO2002080982A9 Nucleic acid mucosal immunization
04/10/2003WO2002080956A3 Use of compounds modulating rxr-ppar heterodimer activity as medicine for treating hepatitis c
04/10/2003WO2002071827A3 Retinoid x receptor modulators
04/10/2003WO2002070540A3 Peptide deformylase inhibitors
04/10/2003WO2002060412A3 Stabilised polymeric aerosols for pulmonary gene delivery
04/10/2003WO2002059083A3 Novel compounds
04/10/2003WO2002050107A3 Streptococcus pyogenes antigens and corresponding dna fragments
04/10/2003WO2002030920A1 Benzimidazole compounds, process for producing the same and use thereof
04/10/2003WO2002028889A3 Haemophilus influenzae antigens and corresponding dna fragments
04/10/2003WO2002009678A3 Charged phospholipid compositions and methods for their use
04/10/2003WO2002008396A3 Human proteases
04/10/2003WO2001092547A9 Modified bovine adenovirus having altered tropism
04/10/2003US20030069428 Pharmaceutically active isoindoline derivatives
04/10/2003US20030069425 Substituted pyrimidine compounds and methods of use
04/10/2003US20030069419 Method for producing 1-substituted-1,2,3- triazole derivative
04/10/2003US20030069393 Compound for use in the treatment of cancer and prevention of infections
04/10/2003US20030069311 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
04/10/2003US20030069301 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
04/10/2003US20030069297 4-aryl substituted indolinones
04/10/2003US20030069287 Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors
04/10/2003US20030069279 Antimicrobial agent
04/10/2003US20030069276 Viricides; aids therapy
04/10/2003US20030069271 Quinolone compounds for use in treating viral infections
04/10/2003US20030069266 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
04/10/2003US20030069243 Novel substituted imidazole compounds
04/10/2003US20030069235 Therapy for eye infections
04/10/2003US20030069228 Capase inhibitors; antiinflammatory agents
04/10/2003US20030069226 Benzothiazole or benzothiazine derivatives of dipyrido(3,2b:2',3'-e)(1,4-diazepin-6-one
04/10/2003US20030069224 Non-nucleoside reverse transcriptase inhibitors
04/10/2003US20030069223 Peptidyl deformylase inhibitors used for inhibiting bacteria or preventing bacterial contamination of a cell culture medium
04/10/2003US20030069222 Used as anti-viral agents against the HIV-1 and HIV-2 viruses.
04/10/2003US20030069205 Anionic polymers including dermatan sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, heparin, dextran sulfate, pentosan polysulfate, hyaluronic acid and alginate.
04/10/2003US20030069204 Strain of streptomyces
04/10/2003US20030069201 Methods of using BCL-2 for the therapeutic treatment and prevention of diseases
04/10/2003US20030069193 Has an activity against MRSA (methicillin-resistant Staphylococcus aureus).
04/10/2003US20030069184 Oligopeptides obtained from the MUCD1 domain of the saliva mucin glycoprotein MUC7 have a net positive charge
04/10/2003US20030068821 Method for expression of small RNA molecules within a cell
04/10/2003US20030068378 Mucosal surface-coat-forming film dosage units containing a water-soluble hydrocolloid, an effective dose of a sexual dysfunction active agent and a mucosal adhesion enhancer, wherein mucosal adhesion enhancer is a starch graft copolymer
04/10/2003US20030068336 Purified capsular polysaccharides from Neisseria meningitidis serogroups are activated and attached to a carriers protein
04/10/2003US20030068334 IBDV strain for in ovo administration
04/10/2003US20030068333 Cocktail of >/= 4 different plasmid DNAs encoding corresponding respiratory syncytial virus antigens, coacervated with chitosan to formulate nanospheres
04/10/2003US20030068328 Live attenuated salmonella strains for producing monovalent or multivalent vaccines
04/10/2003US20030068324 Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid
04/10/2003US20030068315 The polysaccharides in the complexes form an envelope which protects and carries immunoglobulins allowing their systemic absorption through gastric and mucosal membrane; polysacchride and immunoglobulins are bonded by ionic bonds
04/10/2003US20030068302 Optimal compositions and methods thereof for treating HCV infections
04/10/2003US20030068294 Includes at least one keratolytic and cerumenilytic cleaning agent, one bactericide agent, one yeast control agent and one anti-irritant and anti-pruriginous agent; for ear hygiene and for the prevention of otitis in dogs and cats
04/10/2003US20030068283 Composition
04/10/2003US20030068282 Composition
1 ... 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 ... 1798